Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer
Public ClinicalTrials.gov record NCT03162224. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2a, Multi-Center Open-Label Study to Evaluate the Safety and Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic HPV Associated Head and Neck Squamous Cancer
Study identification
- NCT ID
- NCT03162224
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- MedImmune LLC
- Industry
- Enrollment
- 35 participants
Conditions and interventions
Conditions
Interventions
- MEDI0457 Drug
- CELLECTRA®5P device Device
- Durvalumab Drug
Drug · Device
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 25, 2017
- Primary completion
- Mar 18, 2021
- Completion
- Mar 18, 2021
- Last update posted
- Aug 24, 2022
2017 – 2021
United States locations
- U.S. sites
- 14
- U.S. states
- 13
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | San Francisco | California | 94115 | — |
| Research Site | Orlando | Florida | 32806 | — |
| Research Site | Atlanta | Georgia | 30308 | — |
| Research Site | Indianapolis | Indiana | 46202 | — |
| Research Site | Baltimore | Maryland | 21201 | — |
| Research Site | Baltimore | Maryland | 21287 | — |
| Research Site | Detroit | Michigan | 48201 | — |
| Research Site | Minneapolis | Minnesota | 55414 | — |
| Research Site | St Louis | Missouri | 63110 | — |
| Research Site | Morristown | New Jersey | 07960 | — |
| Research Site | The Bronx | New York | 10461 | — |
| Research Site | Winston-Salem | North Carolina | 27157 | — |
| Research Site | Columbus | Ohio | 43210 | — |
| Research Site | Philadelphia | Pennsylvania | 19104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03162224, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 24, 2022 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03162224 live on ClinicalTrials.gov.